Pliva's Win In 5th Circ. Is A Blueprint To Beat 'Off-Label' Suits

By Sindhu Sundar (April 16, 2015, 10:05 PM EDT) -- The Fifth Circuit recently freed Pliva Inc. and other generic-drug makers from claims that their off-label promotion of a generic heartburn drug to treat morning sickness was "dangerous" and led to birth defects. Attorneys say that even though the ruling isn't precedential, it outlines an effective litigation strategy for generic companies that have lately had to field more claims over their marketing....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!